Drug discovery takes too long and costs too much. At Peptris Technologies, AI is reducing preclinical discovery timelines from nearly five years to less than three while maintaining scientific rigour and safety standards. Finding a molecule is not enough. A drug candidate must act on the intended target, avoid off-target effects, reach the right tissue in the right concentration, and be safely metabolised and eliminated. In this video, Narayanan Venkatasubramanian, the CEO and Co-Founder of Pept

Everyone talks about deeptech. But without a strategic playbook, progress becomes slow, fragmented, and vulnerable to mistakes. The founders featured here show the alternative. With a clear framework and the right guidance from IAN Group, they built with precision, avoided avoidable setbacks, and delivered outcomes that trial-and-error simply cannot produce. IAN Group backs this discipline with more than capital. Mentorship, market access, and sustained founder support keep the focus on what act